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Abstract
The National Cancer Institute (NCI) is developing a patient-
reported version of its Common Terminology Criteria for
Adverse Events, called the “PRO-CTCAE.” The PRO-CTCAE
consists of a library of patient-reported itemswhich can be
administered in clinical trials to directly capture the patient
experience of adverse events during cancer treatment, as
well as a software platform for administering these items
via computer or telephone. In order to better understand
the impressions of stakeholders involved in cancer clinical
research about the potential value of the PRO-CTCAE
approach to capturing adverse event information in
clinical research, as well as their perspectives about
barriers and strategies for implementing the PRO-CTCAE in
NCI-sponsored cancer trials, a survey was conducted. A
survey including structured and open-ended questions
was developed to elicit perceptions about the use of
patient-reported outcomes (PROs) for adverse event
reporting, and to explore logistical considerations for
implementing the PRO-CTCAE in cancer trials. The survey
was distributed electronically and by paper to a
convenience sample of leadership and committee
members in the NCI’s cooperative group network,
including principal investigators, clinical investigators,
research nurses, data managers, patient advocates, and
representatives of the NCI and Food and Drug
Administration. Between October, 2008 through February,
2009, 727 surveys were collected. Most respondents
(93%) agreed that patient reporting of adverse symptoms
would be useful for improving understanding of the patient
experience with treatment in cancer trials, and 88%, 80%,
and 76%, respectively, endorsed that administration of
PRO-CTCAE items in clinical trials would improve the
completeness, accuracy, and efficiency of symptom data
collection. More than three fourths believed that patient
reports would be useful for informing treatment dose
modifications and towards FDA regulatory evaluation of
drugs. Eighty-eight percent felt that patients in clinical trials
would be willing to self-report adverse symptoms at clinic
visits via computer, and 68% felt patients would self-report
weekly from home via the internet or an automated
telephone system. Lack of computers and limited space and
personnel were seen as potential barriers to in-clinic self-
reporting, but these were judged to be surmountable with
adequate funding. The PRO-CTCAE items and software are
viewed by a majority of survey respondents as a means to
improve adverse event data quality and
comprehensiveness, enhance clinical decision-making, and
foster patient-clinician communication. Research is ongoing
to assess the measurement properties and feasibility of
implementing this measure in cancer clinical trials.
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Implications
Policymakers: Patient self-reporting provides
essential information about the safety and effec-
tiveness of drugs and devices which can aid
setting treatment and reimbursement priorities.
Researchers: Patient-reported outcomes pro-
vide reliable and valid accounts of the symptoms
experienced by patients during treatment, which
can provide important study data and prompt
new research questions.
Practitioners: Systems that allow patients to self-
report their own side effects in real-time to providers
have been demonstrated to improve symptom
control, patient satisfaction, patient-clinician com-
munication, and to aid in clinical decision-making.
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INTRODUCTION
The Common Terminology Criteria for Adverse
Events (CTCAE) is a lexicon of individual items
maintained by the US National Cancer Institute
(NCI) in order to standardize documentation of
adverse events (AEs) in cancer clinical trials [1].
Initially developed in 1984, it was substantially revised
in 2003 to expand anatomic site specificity and include
criteria for surgical effects, and was again revised in
2009 to harmonize terminology with the Medical
Dictionary for Regulatory Activities [2, 3].
Each CTCAE item contains a term which repre-
sents a specific AE of interest and response options
anchored to discrete clinical criteria which yield a
severity grade between 1 and 5. As such, these items
are used in clinical trials to document both the
incidence and severity of AEs. Three general
categories of AEs are included in the CTCAE: those
based on laboratory reports (e.g., anemia); those
based on clinical observations (e.g., retinal tear); and
symptoms (e.g., dyspnea). All three categories of
items are currently reported by clinicians.
Based onmounting evidence that clinician reporting
of patients’ symptoms underestimates the prevalence
and severity of these symptoms [4–11], and recent
guidance from the FDA regarding standards for the
development of patient-reported outcomes measures
[12], in 2008, the NCI contracted to develop patient
versions of those items in the CTCAEwhich represent
symptoms, which collectively would be called the
“Patient-Reported Outcomes version of the Common
terminology Criteria for Adverse Events” or PRO-
CTCAE. In addition, the NCI contracted to develop a
software platform for administering these items in
clinical trials (although the ultimate intention of the
PRO-CTCAE initiative it to move towards electronic
administration of these items in clinical trials, paper
versions consisting of PRO-CTCAE items will also be
available).
As a part of the PRO-CTCAE initiative, the NCI
wished to ascertain the extent to which various stake-
holders involved in NCI-sponsored trials (particularly
within the NCI’s cooperative group network) recog-
nize a need for such a library of patient-reported AE
items and administration software. Stakeholders of
interest included cooperative group committee lead-
ers, study chairs/principal investigators, clinical inves-
tigators, research nurses, research assistants/data
managers, patient advocates, and representatives of
the NCI and FDA. Of particular interest were
perceived barriers to implementing a system in clinical
trials for electronically collecting patient-reported
adverse symptom information and recommended
solutions for overcoming these barriers.
METHODS
Survey—An anonymous survey was developed to
capture impressions from various stakeholders
involved in the conduct of NCI-sponsored clinical
research about the perceived value, feasibility, and
potential barriers to implementing an electronic soft-
ware platform for capturing patient-reported adverse
symptom events in multicenter oncology trials. Back-
ground questions queried participants’ research role
(s), affiliation(s) with cooperative groups, and educa-
tional degree(s). Additional questions pertained to
barriers to PRO-CTCAE implementation at the
patient-level and site-level, as well as overall impres-
sions of the usefulness of such an approach to
capturing adverse event information. These questions
utilized a common response option format including
strongly agree, somewhat agree, neither agree nor disagree,
somewhat disagree, and strongly disagree. Two open-ended
questions invited general impressions and recommen-
dations for desirable system features. A copy of the
survey is included as an APPENDIX.
Participants—Individuals were eligible to partici-
pate if they were clinical investigators (based at
academic centers or community practices), data
managers, NCI staff, FDA staff, cooperative group
leadership, or patient advocates with direct involve-
ment in the development, conduct, or analysis of
cooperative group trials. Study recruitment targeted
investigators in community oncology practices par-
ticipating in NCI cooperative group research (i.e.,
Community Clinical Oncology Program sites);
patient advocates registered with the NCI; investi-
gators, data managers, and leadership of the Cancer
and Leukemia Group B (CALGB) and Radiation
Therapy Oncology Group (RTOG); FDA reviewers
in the Office of Oncology Drug Products and Study
Endpoints and Labeling Development staff; and NCI
staff in the Division of Cancer Prevention (DCP) and
Cancer Therapy Evaluation Program (CTEP).
Procedure—The survey was uploaded to a secure
electronic distribution system, and an email soliciting
participation was sent to distribution lists of the
targeted participants. In addition, paper versions of
the survey were distributed when disease committees
convened at cooperative group meetings. Because
paper surveys were handed out at multiple coopera-
tive groupmeetings and were also circulated electroni-
cally, it is not possible to quantify the total number of
distributed surveys. The survey indicated to respond-
ents that it was anonymous, and no personally
identifying information was collected. Data were
collected between October, 2008 and February, 2009.
Analyses—Frequencies and proportions were com-
puted for all survey items. Associations between
participant role and various responses were examined
with chi-square analyses. Since some participants
endorsed more than one role, participants were catego-
rized into mutually exclusive groups as Researchers (i.e.,
lead primary investigators, investigators), Research Staff
(i.e., research nurses and research assistants/data man-
agers), Patient Advocates, orRegulators (i.e., NCI and FDA
representatives). Likert responses for each item were
collapsed to create three response options (i.e., Agree,
Neither Agree nor Disagree, Disagree).
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Qualitative responses to the open-ended ques-
tions were evaluated in stages. First, responses were
reviewed for content analysis. Three main themes
were identified: general approval/disapproval of
patient reporting for adverse event monitoring;
concerns about a PRO-CTCAE system; and sugges-
tions for functions of a PRO-CTCAE system. Next,
responses were coded according to these major
themes and grouped into subordinate categories.
Finally, the frequencies of responses within catego-
ries were tabulated.
RESULTS
Participants—A total of 727 questionnaires were
collected between October, 2008 through February,
2009, with the distribution of respondents including
26% researchers, 44% research staff, 14% patient
advocates, and 16% regulators. Ten of the US NCI-
sponsored clinical trials cooperative groups were
included in the survey including the American
College of Surgeons Oncology Group (ACoSOG);
American College of Radiology Imaging Network
(ACRIN); Cancer and Leukemia Group B
(CALGB); Children’s Oncology Group (COG);
Eastern Cooperative Oncology Group (ECOG);
Gynecologic Oncology Group (GOG); National
Surgical Adjuvant Breast and Bowel Project
(NSABP); North Central Clinical Trials Group
(NCCTG); Radiation Therapy Oncology Group
(RTOG); and Southwest Oncology Group (SWOG).
Among the cooperative groups, CALGB (41%) and
RTOG (34%) represented the largest number of
respondents.
Perceived usefulness—Table 1 summarizes survey
responses by participant role. There was strong
consensus (93% overall) that patient reporting of
adverse symptoms would be useful for improving
our understanding of the patient experience with
treatment in cancer clinical trials. The majority of
respondents endorsed that such an approach
would improve the completeness (88%), accuracy
(80%), and efficiency (80%) of symptom data
collection in clinical trials. More than three-
fourths of respondents indicated that patient
reports would be useful for informing treatment
dose modifications and towards FDA regulatory
evaluation of drugs.
Acceptability—Survey responses revealed that 89%
endorsed, with 64% strongly endorsing, the need
for a PRO-CTCAE approach to collect adverse
symptom assessments directly from patients in
clinical trials. Adverse symptom severity was
regarded by 68% to be better understood by
patients than clinicians, particularly among patient
advocates, while research staff disagreed the most,
χ2(6, N=624)=54.64, p<.001. Conversely, 86% of
all respondents agreed that some symptoms may
be better understood by clinicians due to technical
training and expertise. Consistent with these
results, 88% agreed that adverse events in clinical
trials should be reported by both patients and
clinicians.
Implementation barriers—Although 88% of respond-
ents felt that patients in clinical trials would be
willing to self-report adverse symptoms at clinic
visits via computer, 88% believed that severe illness
could be a potential barrier. Inclusion of proxy
reporting by caregivers for patients too ill to self-
report received support by 68%, particularly among
patient advocates, χ2(6, N=619)=15.08, p<.020. A
belief that patients enrolled in clinical trials would
be willing and able to self-report weekly from home
via the internet or via an automated telephone
system was shared by 68%, but research staff were
the most skeptical χ2(6, N=625)=42.88, p<.001.
Most participants agreed that a potential barrier to
patients self-reporting at clinic visits via computer is
the scarceness in the clinical setting of computers
that can be accessed by patients (70%). Other
perceived barriers to this approach included limited
time at clinic visits (58%), limited available person-
nel to assist patients (57%), and limited clinic space
(50%). However, compared with research staff,
fewer patient advocates thought that clinic time,
personnel, or space were barriers. With no signifi-
cant differences between groups, 43% of all respond-
ents agreed that their workload would increase if
patient reports were used for AEs while 42% neither
agreed nor disagreed.
Importantly, 79% of participants perceived that
all potential barriers were manageable if additional
funds could be obtained. Regarding the method of
patient reporting in clinic, 82% indicated that paper-
based reporting was feasible, and relative to elec-
tronic reporting, more respondents thought portable
devices (58%) were feasible compared with desktop
computers (39%). Researchers endorsed the use of
portable devices more than other groups, χ2(6, N=
565)=100.98, p<.001.
Patient advocate respondents were more likely
than other respondent types to endorse that patients
would be willing to self-report from home between
visits. Advocates were also more open to an
approach in which caregivers reported on behalf of
those too ill to report for themselves.
Qualitative responses—Of the total sample of 727
respondents, 292 respondents (40%) provided com-
ments to the open-ended questions. Of these, 24%
offered generally positive statements about a PRO-
CTCAE approach. For example, “Self-reporting of
adverse symptoms is needed. This would improve the
understanding of patients’ reactions to new treatments or
drugs and avoid the problem of patients not telling
clinicians of problems because they do not want to ‘bother’
the doctor. It also makes the patient feel a part of the
research process and not just a ‘guinea pig’ which is very
important.” In comparison, only 3% wrote general
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negative statements, such as, “There are already several
good systems for collecting data of this kind. I am not sure
why additional systems are needed.”
Respondents also commented on potential imple-
mentation barriers and provided suggestions to guide
the optimal design of a system to capture patient-
reported adverse events (see Tables 2 and 3). Themost
frequently reported potential barrier was a concern
that patient self-reports could introduce inaccuracies
into adverse event reporting because of reporting and
recall biases, and lack of knowledge. Other cited
potential barriers included unfamiliarity with elec-
tronic devices, lack of computer access at home, and
limited acceptance of and adherence to reporting
protocols by patients. Additional concerns were that
such an approachmight be a burden to patients, might
generate “needless” data, diminish communication
between patients and doctors, and cause patients to
be overtreated for symptoms.
Multiple suggestions were offered to strengthen
the development of patient-reported AE items and
software, with representative examples shown in
Table 3. The most common recommendation was to
assure that any approach to patient self-reporting be
Table 1 | Responses to stakeholder survey, by respondent role subgroup (N=727)
All
respondents










In general, patients better understand the severity of their symptoms than clinicians
N 624 178 288 86 72 .001
Agree 68% 80% 54% 81% 76%
Neither 13% 12% 15% 7% 13%
Disagree 19% 8% 31% 12% 11%
Caregivers will be able to report on behalf of severely ill or debilitated patients
N 619 175 285 86 73 .020
Agree 67% 59% 68% 83% 66%
Neither 14% 18% 13% 7% 15%
Disagree 19% 23% 18% 11% 19%
Most patients in clinical trials would be willing to self-report symptoms from home on a weekly basis
N 625 178 287 87 73 .001
Agree 68% 76% 57% 85% 70%
Neither 14% 14% 15% 7% 19%
Disagree 18% 11% 28% 8% 11%
Limited space at my clinic site is a potential barrier to implementing a system for collecting data directly from patients
N 577 174 286 65 52 .001
Agree 50% 48% 58% 26% 40%
Neither 21% 13% 15% 54% 40%
Disagree 29% 39% 27% 20% 19%
Limited personnel at my clinic site is a potential barrier to implementing a system for collecting data directly from
patients
N 576 173 285 64 54 .001
Agree 57% 71% 53% 38% 58%
Neither 18% 7% 15% 52% 32%
Disagree 25% 23% 32% 11% 11%
Limited time at my clinic site is a potential barrier to implementing a system for collecting data directly from patients
N 577 174 285 64 54 .001
Agree 58% 69% 55% 44% 54%
Neither 19% 9% 17% 44% 28%
Disagree 23% 22% 27% 13% 19%
Wireless laptop/tablet computer-based patient self-reporting is feasible at my site
N 565 170 285 60 50 .001
Agree 58% 79% 55% 33% 32%
Neither 23% 8% 20% 58% 46%
Disagree 19% 13% 25% 8% 22%
a Includes cooperative group committee leaders, study chairs/principal investigators, and clinical investigators
b Includes research nurses and clinical research assistants/data managers
c Includes representatives of the national cancer institute and food and drug administration
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Table 2 | Common qualitative responses regarding potential barriers to implementing a standardized system for capturing
patient-reported adverse events in cancer clinical trials (N=292)
Potential barriers na Examples
Patient-related
Inaccurate reporting 48 “Some under-report; others appear to over-report.”
“Patients may not give true statements due to
fear they may have to come off study medications.”
“Patients not trained to identify many adverse events.”
Computer literacy 24 “Patients, especially elderly, are not computer literate.”
Lack of computer and internet access 17 “The only reservation is the availability for our patient
access to computers at home and the physician office.”
Acceptance/adherence 15 “Our patient population is a mixture of people who
would love to do this and others who would not want
to and be quite annoyed at the suggestion.” “Worry
about compliance with patients.”
Patient burden 12 “I would like to see this not to become patient’s burden."
Reading literacy 7 “Please be aware of the literacy limitations of other cultures
and educational levels.”
Appropriate for minorities 6 “We have a number of patients who have immigrated
to our community from other countries. Many need
one-on-one help in deciphering both the survey question
and how they should answer.”
Unable/illness 5 “The most seriously ill patients may not report and only
those who are faring well in the trial may report, thus,
skewing the results." “I don't feel that all patients would
be able to self report.”
Inaccurate proxy report 5 “Caregivers can over-state the patient’s condition
and even more frequently under-state the patient’s
condition.”
Site-related
Limited personnel 20 “I am concerned about the workload generated by
this type of system”. “Not enough time, staffing to
facilitate.”
Limited space 6 “This is a great idea, but in our sites, space is a big issue.”
Funding insufficient 6 “Funding will not overcome the barriers.”
Regulatory approval 2 “Too many regulations to allow this process in my setting.”
Study-related
Unnecessary data 8 “We have used a paper review of AEs. It has generated a lot
of spurious data.” “Does the FDA truly want everything a
patient reports including something not related to any
treatment?”
Data discrepancies 5 “I can see discrepancies between what a patient reports
versus what a clinician would report.”
Procedural difficulties 4 “It would be yet another area where we would have
protocol deviations out of our control.” “Electronic
devices can often be misplaced, forgotten, or patients
can forget to save the data.”
Decline enrollment 3 “This self-reporting may be a factor that causes someone
not to consent to trial.”
Treatment-related
Clinical relationship 6 “Patient self-reporting could be helpful but should not
replace communication between doctor and patient.
This tool can't be another reason for patients not to
talk with their doctors.”
Treatment implications 5 “Not every symptom needs a medical treatment.”
“I would be concerned that it may increase the dose
modifications required.”
Staff notification 2 “How does the clinician gain access to this information for
patient care and dose modifications?”
a Some respondents identified more than one potential barrier
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Table 3 | Suggestions by survey respondents for the design of a standardized system to capture patient-reported adverse
events in cancer clinical trials (N=292)
Suggestions na Examples
User friendly
Understandable 41 “Clear definition of the concept measured.” “Give examples.”
“Include pictures.” “Simple short concise verbiage.”
Easy to complete 40 “Touch screen system.” “Drop down menus.” “Quick to complete.”
“Easy to navigate.” “Error correction.”
General comments 37 “User friendly.”
Patient Education 23 “We need much better patient education so that they feel comfortable
reporting events.” “Any reporting system has to be clear about the
reasons for reporting symptoms in order to make sure that patients
don’t withhold things that might be relevant.”
Readable 18 “Large font.” “Minimal words per screen.” “Instructions modified for
people with visual impairment or reading disability.” “Available in
different languages.”
Easy for administrators 13 “Easy to implement for sites.” “Leveraging potential business of
practice incentives to their use may prove to be a way to
accelerate uptake.”
Accessible/portable 12 “Development of portable electronic/tablet systems.” “Accessibility
is important to avoid biases.”
Help support 6 “Help function should be available.”
Cues/Reminders 4 “Auto calls or email to remind patients to self report.” “Prompt
when PRO measures are due and not obtained.”
System features
Reporting options 40 “It would be nice if patients were given a choice of electronic
vs. paper.” “There should be some open ended way for patients
to report.” “The option to self-report daily or more than weekly
as needed.”
Electronic reporting 32 “eTablets were used in a practice I worked in and greatly improved
the assessment of the patients’ symptoms and adjustment of
treatment as needed.” “Should make such a survey a web form.”
“Wireless.” “PDA”
Involve clinician 27 “Best system is probably interactive between patients and staff.”
“Patient self-reporting should always be accompanied by clinician
assessment simultaneously.”
Outside clinic reporting 17 “Reporting between appointments would be very helpful.” “Favor
home reporting due to limited clinic time/space.”
Data quality assurance 9 “Would also need to be reviewed by trials staff to ensure that patient
is reporting all symptoms and events.”
(Differentiate) proxy reports 6 “Caregiver or proxy reporting might be useful to avoid burden to ill
patient or to avoid missing data however it would need to be coded
differently.” “For a pediatric population, the system would have to
allow for parent reporting.”
Patient privacy 4 “Assurance of privacy.”
System development and implementation
Validate 29 “A system such as the one proposed must be validated to withstand
the highest level of scrutiny.” “Use instruments that patients have
reviewed and provided qualitative feedback on.”
Standardize assessment 14 “Good idea but devil is in the detail. There should be a standard
method of reporting.” “Group common AE's together and do not
"repeat" similar questions/events.”
Minimize recall period 10 “Record the information at the time the symptom occurred.”
Obtain additional
information
7 “Include QOL and affective measures.” “Include field to indicate
interventions for AEs.”
Longitudinal assessment 6 “What is of interest is change over time since it is recognized that
some patients have poor baseline scores that are unrelated to




6 “More work needs to be done to examine how different types of
patients communicate with physicians or cancer care teams.”
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user-friendly. Patient reminders and feedback were
proposed to increase adherence, and to facilitate
patient care. Automated alerts to flag severe symp-
toms to research and clinical staff were deemed
important. Respondents advocated that any patient-
reported items and software should be appropriate
for use in a range of patient populations, including
minorities, pediatrics, disabled, non-English speak-
ing, and those with lower literacy and educational
levels. Similarly, system testing within a range of
community settings and not just at large university-
based clinics was encouraged. Respondents also
recommended research on the interpretation of
response choices as some felt that reporting differ-
ences may exist by treatment trajectory, symptom
tolerance, severity of illness, location (e.g., home vs.
clinic), cultural factors, and age (e.g., adolescents).
DISCUSSION
Diverse stakeholders involved with administration of
clinical trials in the NCI-sponsored cooperative group
network endorse development of a system to system-
atically collect patient-reported adverse event informa-
tion. Across several respondent subgroups (i.e.,
cooperative group leadership, investigators, data man-
agers, patient advocates, regulators), the PRO-CTCAE
approach was viewed by most as a means to improve
data quality and comprehensiveness, enhance clinical
decision-making, and foster patient-clinician commu-
nication. Moreover, it was felt that patient-reported
adverse event information should be incorporated into
published study results and drug labels.
Thesefindings reflect an overallmovement in clinical
research and drug regulatory policy towards favoring
patient self-reports for those experiences best known to
the patient, such as symptoms [3–5, 13–18]. Of
particular note is the FDA’s recent guidance for industry
on patient-reported outcomes measures in medical
product development to support labeling claims, in
which patient-reported outcomes (PROs) are advocated
for measuring subjective experiences of patients related
both to treatment benefit and risk [12, 19]. Most HRQL
and symptom instruments focus on treatment benefit,
but the patient perspective on tolerability is rarely
systematically captured. The availability of inexpensive
technologies for administering questionnaires to
patients (e.g., via computer, telephone, or other portable
device), and widespread patient familiarity with these
technologies, have made it feasible to collect informa-
tion directly from patients during cancer treatment [20,
21]. A recent report by the Institute of Medicine
highlights the need for data standardization and
efficiency within the cooperative groups and the
importance of engaging patients in the clinical trial
enterprise; the approach of the PRO-CTCAE is con-
sistent with this report’s recommendations [22].
The results of this survey are being used to inform
pilot feasibility studies of implementing PRO-
CTCAE in NCI-sponsored clinical trials within the
NCI’s cooperative group network. In these pilot
studies, selected PRO-CTCAE items are being
administered electronically to patients enrolled in
several multicenter clinical trials. Outcomes of
interest include cost, logistical requirements for sites,
acceptance by clinical staff and patients, and added
value of collected information.
The PRO-CTCAE approach may yield benefits
beyond screening for and characterizing adverse
symptoms in clinical trials. Longer-term monitoring
of patients’ symptoms can be used to evaluate post-
treatment patterns and timeframes for resolution of
symptoms. It may also aid in symptom monitoring
and management during routine chemotherapy
care.
The stakeholder survey suggests that the largest
perceived barrier to adoption of PRO-CTCAE in
NCI-sponsored trials is the logistics around clinical
implementation. When asked what resources would
be necessary to facilitate computer-based adminis-
tration of PRO-CTCAE items at clinic visits (i.e., at
the point of care), many respondents suggested that
additional computers, staff, and space would be
necessary. This suggests that for an in-clinic elec-
tronic questionnaire administration model of PRO-
CTCAE implementation to be successful, additional
funds would be necessary to support site-level
infrastructure. Alternatively, a model could be
Table 3 (continued)




16 “Customized 'tell your doctor fields’ would add to value for busy
clinics and an automatic email and feedback to data mangers
and investigators on trials.” “Real-time feedback to providers.”
Clinically useful 14 “Include some diagnostic queries.” “Ability of health care personnel
to access patient-reported symptoms to integrate these into
clinical evaluation.”
Helpful for patients 11 “System to categorize the adverse events over time for a patient to
see a pattern or trend.” “The system should be used to provide
24/7 coverage for patients.”
a Some respondents identified more than one potential barrier
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developed in which patients do not rely on clinic-
based computers to report, but rather would report
between visits via home computers or an automated
telephone system. Although training and backup
data collection methods for non-respondents would
still be necessary, much of this could be centralized
or handled by site staff without requiring additional
equipment or physical space at sites. Most respond-
ents felt that such a remote-reporting model would
be feasible.
Research staff (research nurses, research study
assistants, data managers) generally had more con-
cerns than other stakeholders about the logistics and
resources necessary for adding this approach to the
already-complex conduct of clinical trials. These are
understandable concerns for this stakeholder group
given limited resources at study sites for current data
management needs and competing priorities in
clinical trials [23]. Therefore, successful implemen-
tation of the PRO-CTCAE in cancer trials requires
commitment of resources and education of research
staff regarding its value as a data collection tool to
improve the quality, comprehensiveness, and effi-
ciency of AE data collection. Notably, clinical staff
members who have actively participated in pilot
studies including patient-reported AE data have
highly endorsed its use [20].
Of note, patient respondents were more likely
than other respondent types to feel that patients
would be willing to self-report weekly from home
between visits. This bodes well for the use of a
between-visit approach to monitoring patient symp-
toms. It also reveals that clinical staff may under-
estimate the level of patient willingness or
enthusiasm to self-report from home.
The success of broadly integrating use of the PRO-
CTCAE items and software in cancer clinical research
as tools for AE documentation and to enhance clinical
decision-making will likely also depend on their
integration with clinical workflow and in particular
with other electronic systems used to manage clinical
trials and electronic health records [24]. As such, an
emphasis of the PRO-CTCAE initiative is integration
with other clinical systems. [25]
To date, version 1.0 of the PRO-CTCAE items
has been developed, encompassing 78 of the 790
items in CTCAE version 4. [26] Cognitive inter-
views have been conducted in a diverse sample of
patients to assess the content validity of the items,
[27] and a multi-center validation study to assess the
measurement properties of the items is currently
underway. [28] An online portal for administering
these items to patients has been developed [25].
Prior work demonstrates the feasibility of collecting
adverse symptom information directly from patients
during cancer treatment [15, 20, 21], and additional
feasibility studies in the NCI cooperative group
network are ongoing.
In generalizing our findings, it should be recog-
nized that a nonresponder bias may exist since our
sampling procedures did not allow us to determine
the response rate, and respondents comprise a
convenience sample of those investigators, data
managers, patient advocates, and regulators who
were willing to participate. As a result, there may be
unaccounted-for differences between survey res-
ponders and nonresponders in their perceptions
about patient self-reporting of adverse events. How-
ever, given the size and diversity of our sample, we
speculate that the high levels of overall endorsement
observed in our study are comparable to the view-
points of a majority of stakeholders.
As most participating investigators were aca-
demics and community-based practitioners work-
ing within the NCI’s cooperative group network,
their sentiments may not extend to industry,
where most preapproval drug development is
conducted. However, many academic investiga-
tors serve as thought-leaders and advisors to
industry. Nonetheless, ascertainment of sentiments
towards such systems among stakeholders in the
pharmaceutical industry would necessitate addi-
tional study. Notably, other research is being
conducted to evaluate the extent to which patient
self-reporting of would affect the frequency of
reporting of adverse symptoms in clinical trials
compared with the current clinician-reporting
approach. It has been hypothesized that the
frequency of adverse symptoms not attributable
to products being studied (e.g., related to comor-
bidities or “noise”) would actually be reduced,
while the power to detect adverse symptoms
attributable to products themselves would be
increased. Such properties would be appealing to
sponsors and regulators, but these evaluations are
pending.
The overall goal of a clinical trial is to collect
valid and reliable data about the efficacy and
adverse event profile of an intervention. This
information is used by investigators to understand
the properties of that intervention; by regulators
to assess its overall value to the public; and by
clinicians and patients during informed decision-
making. It has become clear that the current
mechanism for collecting adverse symptom event
information in trials does not adequately represent
the patient subjective experience with treatment.
As a consequence, the information about toler-
ability that is available to investigators, regulators,
clinicians, and patients when making decisions is
incomplete. To alleviate this gap, an approach to
systematically and efficiently collect patient-
reported adverse symptom events is indicated,
and the PRO-CTCAE represents one such
approach. The ultimate goal of this work is to
enhance the quality of information about the
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impact of treatment on patients, to better inform
decision-making and to improve patient safety.
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NCI is developing a system for patients to report their own adverse symptoms in clinical 
treatment trials, called the PRO-CTCAE.  This system will allow patients to self-report 
selected CTCAE symptoms electronically (by computer) or via paper forms at clinic 
visits. Clinicians and investigators will have access to this information for treatment 
decisions and/or documentation.  We are seeking your input to assist us in 
understanding potential barriers to implementing such a system in the multicenter clinical 
trial setting.
1(a). What is your current role (check all that apply):
__Lead PI on treatment trial protocols 




__Member of cooperative group committee




__Representative of industry sponsor 

















__MPH or other Master’s
__BA or BS
3. Have you worked with cancer populations?
__Yes __No 
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Please indicate how you perceive potential barriers to implementing a system for 














Most patients participating in clinical trials of 
cancer treatment would be willing to self-report 














If patients feel well enough to attend a clinic visit, 
they are likely able to self-report their symptom 
burden
4b
Severe illness or debilitation is a potential barrier 
to patient self-reporting
4c
Caregivers will be able to report on behalf of 
severely ill or debilitated patients
4d
Caregivers should be allowed to report symptom 
burden on behalf of severely ill or debilitated 
patients
4e
Most patients in clinical trials would be willing to 
self-report symptoms from home on a weekly 
basis (ie, by computer, automated telephone 
system, handheld device, etc)
4f
5. CLINIC/STUDY SITE ISSUES 
Limited space at my clinic site is a potential barrier 
to implementing a system for collecting data 
directly from patients
5a
Limited personnel at my clinic site is a potential 
barrier to implementing a system for collecting 
data directly from patients
5b
Limited time at my clinic site is a potential barrier 
to implementing a system for collecting data 
directly from patients
5c
Lack of computers for patients to use for self- 
reporting is a potential barrier at my clinic site
5d
The above potential barriers could be overcome 
with adequate funding 
5e
My clinic site has research staff who could likely 
assist patients with self-reporting symptoms in 
clinical trials if such a system were adopted 
5f
There are areas at my clinic site that could be 
configured for patient self-reporting
5g













My clinic site has computers that could likely be 
adapted for use by patients to self-report 
symptoms in clinical trials
5h
My site would need to acquire new computers for 
patient-reporting if such a system were adopted
5i
Desktop computer-based patient self-reporting is 
feasible at my site
5j
Wireless laptop/tablet computer-based patient 
self-reporting is feasible at my site
5k
Paper-based patient self-reporting is feasible 
at my site
5l













Systems to efficiently collect patient self-reported 
adverse events in clinical trials should be 
developed
6a
In general, patients better understand the severity 
of their symptoms than clinicians
6b
There are some symptoms which clinicians better 
understand than patients
6c
In clinical trials, adverse symptoms should only be  
reported by patients and should not be separately 
reported by clinicians
6d
In clinical trials, adverse symptoms should only be 
reported by clinicians and should not be separately 
reported by patients 
6e
In clinical trials, adverse symptom information 
should be reported by both patients and clinicians
6f
Both patient-reported and clinician-reported 
adverse symptom information should be reported 
in clinical trial results, and in drug labels
6g
Patient self-reporting of adverse symptoms in trials 
would decrease my workload
6h
Patient self-reporting of adverse symptoms in trials 
would increase my workload
6i
Patient self-reporting of adverse symptoms from 
home between visits could provide valuable data 
for assessing drug toxicities in clinical trials
6j
If patient-reported adverse symptoms were 
included in drug labels, clinicians would use this 
information to help describe the consequences of 
treatment to future patients, and to shape 
treatment recommendations
6k
TBMpage 120 of 122
1. National Cancer Institute, National Institutes of Health, U.S.
Department of Health and Human Services. Common Terminol-
ogy Criteria for Adverse Events (CTCAE) Version 4.0. NIH
publication # 09-7473. Published May 29, 2009; Revised
Version 4.02 September 15, 2009 (available at http://evs.nci.
nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReferen
ce_5x7.pdf, last accessed December 30, 2010).
2. Trotti, A., Colevas, A. D., et al. (2003). CTCAE v3.0: development of a
comprehensive grading system for the adverse effects of cancer
treatment. Seminars in Radiation Oncology, 13(3), 176–181.
3. Trotti, A., Colevas, A. D., Setser, A., & Basch, E. (2007). Patient-
reported outcomes and the evolution of adverse event reporting
in oncology. Journal of Clinical Oncology, 25(32), 5121–5127.
4. Fromme, E. K., Eilers, K. M., et al. (2004). How accurate is
clinician reporting of chemotherapy adverse effects? A compar-
ison with patient-reported symptoms from the quality-of-life
questionnaire C30. Journal of Clinical Oncology, 22(17), 3485–
3490.
5. Basch, E. (2010). The missing voice of patients in drug-safety
reporting. The New England Journal of Medicine, 362(10), 865–869.
6. Pakhomov, S. V., Jacobsen, S. J., Chute, C. G., & Roger, V. L.
(2008). Agreement between patient-reported symptoms and
their documentation in the medical record. American Journal of
Managed Care, 14, 530–539.
7. Schnadig, I. D., Fromme, E. K., et al. (2008). Patient-physician
disagreement regarding performance status is associated with
worse survivorship in patients with advanced cancer. Cancer,
113(8), 2205–2214.
8. Parliament, M. B., Danjoux, C. E., et al. (1985). Is cancer
treatment toxicity accurately reported? International Journal of
Radiation Oncology, Biology, Physics, 11(3), 603–608.
9. Basch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris,
M. G., et al. (2006). Clinician versus patient self-reporting of
symptoms during cancer treatment: a paired analysis using the
national cancer institute’s common terminology criteria for
adverse events (CTCAE). The Lancet Oncology, 7(10), 903–909.













Providing information to inform treatment dose 
modifications in clinical trials
7a.
Improving efficiency of data gathering in clinical 
trials
7b.
Improving the completeness of symptom data 
collection in clinical trials
7c.
Improving the accuracy of adverse event 
documentation in clinical trials 
7d.
Providing information for FDA to use when 
evaluating the toxicities of drugs  
7e.
Providing toxicity information for use in drug labels 7f. 
Improving our understanding of the patient 
experience with treatment
7g.
8. General comments, suggestions, or feedback are welcome and encouraged:
9. What features would you want to see in a system for patient self-reporting of 
adverse events in clinical trials?
Please feel free to email any additional comments, or interest to become involved
in this effort, to Laura Sit (sitl@mskcc.org).
Thank you for taking the time to share your viewpoints, which we hope to use to design
a useful and valuable system.
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